Loading clinical trials...
Loading clinical trials...
A Phase 3, Randomized, Placebo-controlled, Observer-blinded, Trial To Assess The Safety, Tolerability, And Immunogenicity Of Bivalent Rlp2086 Vaccine When Administered As A 3-dose Regimen In Healthy Young Adults Aged >=18 To <26 Years
Conditions
Interventions
rLP2086
Placebo
Locations
58
United States
Coastal Clinical Research, Inc.
Mobile, Alabama, United States
Clinical Research Advantage, Inc./Desert Clinical Research, LLC
Mesa, Arizona, United States
Clinical Research Advantage, Inc./ Fiel Family and Sports Medicine, PC
Tempe, Arizona, United States
Clinical Research Advantage, Inc./ Fiel Family and Sports Medicine, PC
Tempe, Arizona, United States
Anaheim Clinical Trials LLC
Anaheim, California, United States
eStudySite
La Mesa, California, United States
Start Date
May 1, 2013
Primary Completion Date
February 1, 2015
Completion Date
February 1, 2015
Last Updated
February 23, 2016
NCT00104325
NCT07090785
NCT07526506
NCT06431932
NCT00090662
NCT06290258
Lead Sponsor
Pfizer
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions